2011-10-14 2011-10-14Cologne, 14 October 2011. Nexigen GmbH, a biopharmaceutical company developing therapeutic peptides to fight cancer, announced the appointment of Dr. Jörg Vollmer as CEO and member of the management board of the company. Dr. Vollmer is the former CEO of Coley Pharmaceutical GmbH, a subsidiary of Pfizer Inc., and brings in experiences from both biotech and pharma. The acquisition of Dr. Vollmer will strongly support the current growth phase of the company to become a leading drug developer for innovative therapeutics in cancer.
Nexigen GmbH is in the process to extend its activities from drug discovery towards drug development. In order to support the rapid growth the company appointed Dr. Jörg Vollmer as CEO and member of the management board.
Dr. Vollmer was formerly Managing Director of Coley Pharmaceutical GmbH, a subsidiary of Pfizer Inc. Between 2008 and 2011 Coley Pharmaceutical did belong to the Pfizer Research. Therefore he brings in management skills from both the biotech and pharma world. As part of Pfizer’s Oligonucleotide Therapeutics Unit (OTU) he concentrated on the development of nucleic acid therapeutics to suppress disease genes such as siRNA and antisense. This field perfectly matches Nexigen’s positioning as a developer of innovative drugs targeting so far inaccessible disease mechanisms.
Before 2008 Dr. Vollmer held several senior management positions at Coley Pharmaceutical Group, latest as Vice President Discovery & Development. In this role he was responsible for the identification and evaluation of novel product candidates and new research and application areas. Coley Pharmaceutical was a pioneer in developing a class of drug candidates called TLR Therapeutics, oligonucleotide drugs to modulate the immune system. Dr. Vollmer holds a degree in Biology from the University of Freiburg and has a PhD in Immunology from the Max-Planck-Institute of Immunobiology.
Dr. Vollmer is Member of the Board of the biotechnology cooperation BioRiver e.V. in North Rhine-Westphalia.
“With his broad experience in Discovery & Development and the pharmaceutical industry Dr. Vollmer is the ideal candidate for this key position within our company”, said Dr. Hanjo Hennemann, CSO and founder of Nexigen. “Nexigen’s proprietary peptide platform has the potential to enable successful development of peptide modulators targeting disease mechanisms which traditionally have not been accessible for drug discovery. I am excited to work with Hanjo Hennemann and his team and to contribute to the future success of Nexigen”, comments Dr. Jörg Vollmer, Managing Director and CEO of Nexigen.
The appointment of Dr. Vollmer as CEO of Nexigen strengthens the company in its process to become one of the leading drug developers for innovative therapeutics with novel potentially superior properties and associated important USPs.
About Nexigen GmbH
Nexigen GmbH was founded in August 2007, obtained its first capital in 2008 und develops peptide therapeutics with novel mode of action for the treatment of cancer. The company aims at so far inaccessible proteins, which are crucially involved in the onset and progression of tumors. Nexigen relies on proprietary and innovative peptide screening technologies in living cells. This allows for the time and cost-efficient access to drug discovery. Currently Nexigen GmbH cooperates with various biotech companies and successfully completed projects with leading pharmaceutical companies
Please contact us for further information!
Daniela Thiebes Nexigen GmbH
+49 (221) 33 77 72-00 thiebes (at) nexigen.de
Download Press release
2011-06-01Nexigen GmbH, a biopharmaceutical company closed a financing round totalling 4.1 mio Euro with the participation of new and existing investors. The fresh capital enables Nexigen to reach strategic goals in the development of novel drugs against cancer by 2013:
2011-05-09This year’s Peptide Therapeutics part of the TIDES conference is focusing on “Modulators of Previously "Undruggable" Targets and Disease Mechanisms”. Recently a novel class of drugs, cell-permeable peptides, appeared under the radar of biotech and pharma companies. These peptide modulators are able to target disease mechanisms, which traditionally have not been accessible for drug discovery, resulting in drugs with high USPs. Dr Hanjo Hennemann, Executive Director and Head of R&D, Nexigen GmbH will talk at TIDES and will give insights to this emerging field, discuss novel modes of actions, and provide examples from the use of Nexigen's discovery platform of intracellular peptide modulators.
More information can be obtained here.
2010-07-05Hanjo Hennemann, managing director and head R&D of Nexigen GmbH will give a presentation on “Intracellular peptides: novel modulators for drug discovery and high content target validation” at 5th Assay and Drug Discovery Technologies Conference (San Diego, CA Sept. 20-21, 2010). This presentation will address intracellular peptides for the modulation of non-enzymatic drug target proteins. Currently intracellular peptide therapeutics receive increasing attention as a validated alternative to siRNA-therapeutics. In addition, Dr. Hennemann will talk about innovative peptide discovery technologies, and the novel use of intracellular peptides as drug-like tools for target validation.
More information can be obtained here.
2010-04-16Download press release
Download german press release
2010-03-10Nexigen’s scientific head and executive director, Dr. Hanjo Hennemann will present the class of intracellular peptide therapeutics at the conference Next Generation Protein Therapeutics Summit (June 21-23, 2010, San Diego, USA). The talk will be held in the new conference format “Crossing the Barriers”, owing to the increasing importance of intracellular drug targeting of peptides and other biologics. Dr Hennemann will also review recent developments of Nexigen, in particular the application of Nexigen’s proprietary screening platform for the selection of peptides inside of living eukaryotic cells.
More information can be obtained here.
2009-05-27Nexigen's novel peptide screening technology is drawing increasing attention in the pharmaceutical industry. Nexigen's head of research Dr Hanjo Hennemann will introduce to intracellular peptide drugs at the 2009 Peptides Europe conference (Sept. 17-18, 2009) in Berlin. Nexigen is an emerging biotechnology company which develops innovative peptide-derived drugs with novel mode of action.
2009-05-04Dr Hanjo Hennemann, managing director of Nexigen, will give a presentation at the 2009 Assay Development & Screening Technologies Conference (June 8-9, San Francisco, CA). He will talk about intracellular peptides an emerging drug class, which is able to address so far inaccessible disease mechanisms.
2008-10-31Nexigen GmbH started a collaboration with an undisclosed global top10 pharma company. The study involves a screening project in oncology.
2008-05-20From June 17 - 20 Nexigen will attend the 2008 BIO International Convention in San Diego, the world's biggest biotech partnering conference. Nexigen will present recent developments and its screening capabilities.
2008-04-29Nexigen GmbH closed an investment round involving Santo Holding (Deutschland) and the biotech company 4SC AG. This investment will allow Nexigen to proceed its ongoing drug discovery programs (anti-infectives) and also extend its pipeline with drug discovery projects in oncology.
2008-01-21After the successful completion of trials over the past year, Nexigen GmbH and Phylogica Ltd. (Subiaco, Australia) signed a letter of intent for the worldwide co-marketing of the screening services offered by both companies. The trials included peptide screening with an undisclosed target using Nexigen's in vivo peptide screening platform and Phylogica's Phylomer® library. The trials confirmed the broad usability and high functional hit rate of the automated Nexi Peptide Screening platform in combination with highly diverse Phylomer® libraries.
More information can be obtained here.
2007-11-05In October, 2007, Nexigen successfully completed a screening project with an undisclosed protein kinase, a drug target in oncology, with Johnson & Johnson Pharmaceutical Research & Development.
2007-09-09From November 12th - 14th, 2007, Nexigen will participate at the 13th annual international biotechnology conference in Hamburg. Technology and producs will be presented at the Nexigen booth.
2007-09-07Today Nexigen GmbH was officially registered by the German authorities. The company aims at the development and licensing of drugs and diagnostics.
2007-08-06In July 2007, we successfully finished a research cooperation with Bayer-Schering, Germany. The goal of this cooperation was the analysis of a cancer-relevant proteins (drug targets) using Nexigen's proprietary screening technology. The results provided Bayer-Schering with valuable information regarding the molecular function of this target and its role in disease.
2007-03-12From May 6th-9th, 2007, Nexigen will participate at the world largest biotechnology partnering conference in Boston. Technology and products will be presented.
© 2007-2012 Nexigen GmbH
Source: http://en.nexigen.de/news